AFFX Affymetrix, Inc.

Affymetrix Microarray Bulletin (AMB) today published interviews with researchers from the Scripps Research Institute and Imperial College London who are using microarrays to understand the pathogenesis of Malaria-causing Plasmodium falciparum and the hypervirulent Beijing/W Tuberculosis strain. Headlines for Feb. 15, 2006 AMB Issue: -- Microarray Analysis Characterizes Function of 95% of Malaria-causing Plasmodium falciparum Genes, Three Times More than Ever Before: The Scripps Institute's Elizabeth Winzeler and the Sanger Institute's Celine Carret discuss recent advances in malaria research made possible using whole-genome Plasmodium microarrays -- Researchers Discover Large Genomic Deletions in Hypervirulent Beijing/W Tuberculosis Strains: Imperial College London's Anthony Tsolaki and McGill's Serge Mostowy discuss the large genetic differences found among strains of Mycobacterium tuberculosis To view the complete stories, please visit: http://microarraybulletin.com/community Affymetrix Microarray Bulletin (AMB) is a magazine published by Affymetrix, Inc. (Nasdaq:AFFX) that highlights leading microarray research and diagnostic developments around the world. AMB features interviews by and for scientists, statisticians and software engineers -- one expert interviewing another. Our goal is to create a forum where this community can discuss research and share new resources and information. For more information about AMB, please visit the publication's website at www.microarraybulletin.com About Affymetrix: Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,300 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif. with subsidiaries in Europe and Asia, as well as manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 1,000 employees worldwide. For more information about Affymetrix, please visit the company's website at www.Affymetrix.com. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.